Media-WIND Health Strategies and MediCloud Biotech earn SGS ISO 9001 recertification with zero findings in patient support program quality management

In the highly specialized and tightly regulated field of pharmaceutical management and patient support services, a quality management system (QMS) is the foundation of service reliability and a concrete commitment to patient safety and privacy. Media-WIND Health Group (MWHG) (PatientsForce), a long-standing leader in this field, announced that its two core subsidiaries — Media-WIND Health Strategies Co., Ltd. and MediCloud Biotech Co., Ltd. — have once again passed SGS ISO 9001 quality management system recertification. The achievement not only underscores the group's unwavering commitment to excellence, but also lays a forward-looking foundation for its digital and sustainability agenda in 2026.

Eight unbroken years of quality commitment: a QMS safeguarding the patient journey

This ISO 9001 certification continues a long-term quality commitment that began with the group's first certification in 2018. The scope covers both Media-WIND Health Strategies and MediCloud Biotech, demonstrating that the group has successfully embedded the same high-standard quality management DNA across its service organization. PatientsForce — the core brand behind Media-WIND Health Strategies's professional advisory services and MediCloud Biotech's smart healthcare solutions — places quality at the heart of its Patient Support Program (PSP) services.

For patient support programs, a mature and stable QMS is critical in several ways:

Strengthening compliance and transparency: standardized, traceable and measurable workflows ensure that patient assistance and support services (such as PSP, PAP, drug safety and disease management) meet the highest regulatory and ethical standards while making services more transparent.
Operational stability and continuous improvement: a PDCA (Plan-Do-Check-Act) culture in continuous operation since 2018 enables the group to maintain operational stability in a fast-changing biomedical environment, making it a Patient Solution Partner that global pharmaceutical companies and healthcare systems can trust for the long term.
A cornerstone of ESG governance: the group regards ISO 9001 as a key pillar of the "corporate governance" dimension of its environmental, social and governance (ESG) framework, demonstrating its commitment to sustainable development.

Getting ahead of 2026: bringing AI ethics and ESG into risk governance

Notably, with a new edition of the ISO 9001 standard due for release in 2026, the company has already taken proactive steps. As a key partner in the supply chain, the group has incorporated emerging risks into its governance framework ahead of schedule, including:

AI governance and risk assessment: with a focus on data ethics, model reliability and patient privacy protection.
Environmental and climate-change risk assessment: responding to ESG and sustainability trends by embedding environmental responsibility into service processes, with an EcoVadis medal already earned and an SBTi net-zero commitment in place.

Thanks to the efforts of the management team and the compliance center, the company once again passed SGS ISO 9001 certification in 2025. Quality certification is not a finish line, however, but a milestone in an ongoing, effective PDCA cycle. Going forward, the PatientsForce brand will continue to optimize every key touchpoint along the patient journey — from pre-launch Early Access Programs (EAP) to post-launch PAP and PSP — turning "compliance" into "provable value" and building a safer, smarter and more sustainable future of care for patients and the healthcare system alike.